Biocompatible Polymeric Nanocomplexes As an Intracellular Stimuli-Sensitive Prodrug for Type-2 Diabetes Combination Therapy

Feng-Zhen Wang,Zhi-Shen Xie,Lei Xing,Bing-Feng Zhang,Jia-Liang Zhang,Peng-Fei Cui,Jan-Bin Qiao,Kun Shi,Chong-Su Cho,Myung-Haing Cho,Xiaojun Xu,Ping Li,Hu-Lin Jiang

DOI: https://doi.org/10.1016/j.biomaterials.2015.09.013

IF: 14

2015-01-01

Biomaterials

Abstract:Combination therapy is usually considered as a promising strategy owing to its advantages such as reduced doses, minimized side effects and improved therapeutic efficiency in a variety of diseases including diabetes. Here we synthesized a new highly intracellular stimuli-sensitive chitosan-graft-metformin (CS-MET) prodrug by imine reaction between oxidative chitosan and metformin for type 2 diabetes (T2D) therapy. Hypothetically, CS-MET functions dually as an anti-diabetes prodrug as well as a gene delivery vector without superfluous materials. CS-MET formed nanocomplexes with therapeutic gene through electrostatic interactions and entered cells by Organic Cation Transporter (OCT)-independent endocytosis. The incorporation of metformin into chitosan has been found to increase endosomal escape via the proton sponge effect. When vector carrying a short-hairpin RNA (shRNA) silencing sterol regulatory element-binding protein (SREBP), a major transcription factor involved in de novo lipogenisis, it reduced the SREBP mRNA and proteins efficiently. Furthermore, by intraperitoneal injection, CS-MET/shSREBP nanocomplexes effectively knocked down SREBP in livers of western-type diet (WD)-induced obese C57BL/6J mice, markedly reversed insulin resistance and alleviated the fatty liver phenotype without obvious toxic effects. Thus we were able to show that the intracellular stimuli-sensitive CS-MET prodrug renders a potential platform to increase the anti-diabetes activity with synergistic enhancement of gene therapy.